AXSM

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is developing and delivering novel therapies for the central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of the major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Its AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. Its AXS-07 is a multi-mechanistic, investigational medicine under development for the acute treatment of migraine.